Many patients with Coronavirus Disease 2019 (COVID-19) present with pulmonary infiltrates and rapidly progress to severe disease characterized by refractory hypoxemia requiring mechanical ventilation ([@bib0005]). Elevated levels of C reactive protein (CRP) and Interleukin-6 (IL-6), reflecting an hyperinflammatory response, identify patients with progression to refractory hypoxemia ([@bib0010]).

Subcutaneous tocilizumab (TCZ), a humanized anti-IL-6 receptor antibody, is approved for the treatment of rheumatoid arthritis, giant-cell arteritis and cytokine storm related to cancer therapeutics. Recent reports have suggested that high-dose intravenous TCZ (8 mg/kg) may be an effective treatment for severe-to-critical COVID-19 patients, for its ability to rapidly reduce fever and pro-inflammatory markers, and improve oxygenation ([@bib0015], [@bib0020], [@bib0025], [@bib0030]). Whether TCZ can be administered subcutaneously in patients with moderate COVID-19 pneumonia and hyperinflammation to prevent progression to severe disease remains unknown.

We herein present a retrospective analysis of clinical characteristics and outcomes of ten consecutive patients (6 males, median age 55 years) with laboratory-confirmed COVID-19 bilateral pneumonia, hyperinflammation (CRP ≥ 20 mg/dl), no hypoxemia (oxygen saturation \>90% on room air) and no contra-indications to TCZ including bacterial or fungal infection, neutropenia or liver injury, who were treated with TCZ 324 mg, administered subcutaneously in two simultaneous 162 mg injections within 48 hours from admission, on top of standard of care (SOC) at Pescara General Hospital, Italy, between March 28 and April 21, 2020. Patients signed an informed consent for the off-label use of TCZ. Ten hospitalized COVID-19 patients matching for sex, age, and the same treatment criteria, who received SOC in the same institution between March 7 to 27, 2020, served as controls ([Table 1](#tbl0005){ref-type="table"} ). Clinical data were available for all patients until death or, for those discharged from hospital, additional clinical information was obtained by phone contact at 35 days. Data are presented as median and interquartile range (IQR). Within-group changes were compared using the Wilcoxon test for paired analysis, and between-groups differences were analyzed using the Mann-Whitney test for unpaired test.Table 1Clinical characteristics at baseline.Table 1TCZ + SOC group\
(n = 10)SOC group\
(n = 10)GenderMale6 (60%)6 (60%)Female4 (40%)4 (40%)Age55 (54-60)56 (49-60)Smoker2 (20%)1 (10%)Chronic underlying comorbiditiesArterial hypertension4 (40%)4 (40%)Diabetes mellitus2 (20%)3 (30%)Coronary heart disease1 (10%)0Chronic kidney disease1 (10%)1 (10%)Obesity2 (20%)0Malignancy1 (10%)0Signs and symptoms on admissionFever10 (100%)10 (100%)Cough8 (80%)6 (60%)Dyspnea1 (10%)1 (10%)Fatigue or myalgia4 (40%)1 (10%)Nausea, vomit or diarrhea2 (20%)0Headache or confusion1 (10%)0Symptoms onset to hospitalization5 (4-8)5 (3-6)Vital signs on admissionSystolic blood pressure, mmHg135 (130-140)120 (115-125)Diastolic blood pressure, mmHg80 (75-90)75 (75-75)Heart rate, beats per minute87 (78-90)86 (78-103)Respiratory rate, breaths per minute17 (15-18)16 (15-20)Oxygen saturation, %96 (95-96)96 (95-98)Concomitant pharmacologic treatment during hospital stayHydroxychloroquine9 (90%)10 (100%)Darunavir/cobicistat05 (50%)Lopinavir/ritonavir02 (20%)Systemic corticosteroids6 (60%)5 (50%)Oxygen therapy during hospital stayNone10 (100%)6 (60%)Nasal cannulas or mask03 (30%)Non-invasive mechanical ventilation02 (20%)Invasive mechanical ventilation02 (20%)

Treatment with TCZ was well-tolerated with no clinically relevant adverse events. In particular, none of the patients experienced neutropenia (absolute neutrophil count \<1000/mm3), bacterial infections, or liver injury (elevation in alanine aminotransferase 5 times above normal value) (Supplementary Table 1).

Treatment with TCZ was associated with a reduction in CRP at day 1 (-50%, IQR -28 to -80) and day 3 (-89%, IQR -79 to -96; P = 0.005 for within-group), whereas there was no significant change in CRP values in the SOC group (P \< 0.001 for between-groups comparisons at both time points, [Figure 1](#fig0005){ref-type="fig"} A).Figure 1(A) Changes in C reactive protein and P/F ratio. Interval changes are shown in C reactive protein (CRP) and partial pressure of oxygen to fraction of inspired oxygen (P/F), a measure of hypoxemia, in the patients who received tocilizumab on top of standard of care (SOC)(N = 10) as compared with patients who received standard of care only (SOC)(N = 10). Patients receiving tocilizumab had a significant improvement in CRP and P/F at 1 and 3 days (P = 0.005 for within-group changes at each timepoint). No significant changes were seen in the patients receiving SOC only (all P \> 0.05). When compared with patients receiving SOC only, patients receiving tocilizumab on top of SOC had a significantly greater reduction in CRP and improvement in P/F ratio (P \< 0.001 for between-groups differences at each timepoint). (B) Survival free of respiratory failure. Patients receiving tocilizumab (TCZ) on top of standard of care (SOC) were significantly less likely to need oxygen therapy (by means of nasal cannulas, non-invasive mechanical ventilation or mechanical ventilation) than patients treated with SOC only matched for sex, age, and severity of illness (Log-rank Mantel Cox Chi-square 6.367, P = 0.012).Figure 1

In parallel, treatment with TCZ resulted in an improvement of oxygenation, as assessed by the ratio of partial pressure of oxygen to fraction of inspired oxygen (P/F) ratio, which significantly increased at day 1 (+11%, IQR + 6 to +16; P = 0.005 for within-group, and P = 0.006 for between-groups comparisons), and day 3 (+23%, IQR + 16 to +34; P = 0.005 for within-group, and P = 0.003 for between-groups comparisons, [Figure 1](#fig0005){ref-type="fig"}A).

None of the patients treated with TCZ had disease progression defined as requirement of oxygen therapy or mechanical ventilation ([Figure 1](#fig0005){ref-type="fig"}B). At day 14, 8 patients had been discharged and 2 were still in-hospital without need for oxygen therapy. At day 35, all patients had been discharged without supplemental oxygen (Supplementary Table 2). Among the SOC group, COVID-19 progressed in 5 (50%) patients: 3 (30%) patients required supplemental oxygen through nasal cannulas or mask, and 2 (20%) non-invasive mechanical ventilation (NIV) first, and invasive mechanical ventilation (IMV) afterwards, and one subsequently died ([Figure 1](#fig0005){ref-type="fig"}B). At day 14, 5 patients had been discharged without supplemental oxygen and 5 were still in-hospital (3 without supplemental oxygen, one requiring NIV and one IMV). At day 35, 8 patients were discharged without supplemental oxygen and 2 were still in-hospital (one without supplemental oxygen, and one requiring IMV) (Supplementary Table 2).

Our findings suggest that early IL-6 receptor blockade with TCZ may reduce the risk of progression to severe disease in hospitalized patients with moderate COVID-19 pneumonia and hyperinflammation. SARS-CoV viruses trigger an inflammasome-mediated response characterized by high levels of Interleukin-1β (IL-1β) ([@bib0035]), and IL-1β blockade with anakinra or canakinumab has been shown to be associated with more favorable outcomes ([@bib0040], [@bib0045]). Moreover, the IL-1β derived from the inflammasome, as well as the IL-1α isoform, released from dying alveolar epithelial cells, induce the expression of IL-6, which plays a key role in lung injury and refractory hypoxemia. Intravenous IL-6 blockers are often provided on a compassionate-use basis to severe-to-critical COVID-19 with reported beneficial effects ([@bib0015], [@bib0020], [@bib0025], [@bib0030]), and are currently under investigation in randomized controlled trials. Recent studies reported on favorable outcomes with subcutaneous TCZ (324 mg) in patients with severe COVID-19 ([@bib0050], [@bib0055]). However, many patients with COVID-19 have moderate disease not requiring supplemental oxygen. Hyperinflammation may promote disease progression as indicated by higher levels of inflammatory biomarkers being associated with dire outcomes ([@bib0010]). Notably, dexamethasone was recently reported to reduce mortality in COVID-19 patients with respiratory failure, but not in those not requiring supplemental oxygen ([@bib0060]).

The study has several limitations primarily being the small number of patients included, the non-random nature of the comparisons, and the possible immortal time bias.

We herein report on the innovative use of early subcutaneous TCZ in hospitalized patients with moderate COVID-19 who are at risk for progressive disease. Despite preliminary, our data appear reassuring in terms of safety, and compare favorably with those of patients treated with SOC in our center and other published cohorts ([@bib0005]).
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